CYP19A1 and breast cancer: Endocrine therapy (ET) targeting estrogen signaling, primarily with selective estrogen receptor modulators (SERMs) such as tamoxifen and/or aromatase inhibitors (AI) blocking E2 biosynthesis or with the selective estrogen receptor downregulator (SERD) fulvestrant, is currently a standard treatment for patients with ERα-positive BC [6].